Bezafibrate Induces a Mitochondrial Derangement in Human Cell Lines: A PPAR-Independent Mechanism for a Peroxisome Proliferator

Chemical Research in Toxicology

Volumn 16, Issue 11, 2003, Pages 1440-1447

  Scatena, R ^a   Bottoni, P ^a   Vincenzoni, F ^a   Messana, I ^b   Martorana, G E ^a   Nocca, G ^a   De Sole, P ^a   Maggiano, N ^a   Castagnola, M ^a   Giardina, B ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

6 PHOSPHOFRUCTOKINASE; ACETIC ACID; ALANINE; BEZAFIBRATE; CIGLITAZONE; CLOFIBRIC ACID; GEMFIBROZIL; LACTIC ACID; MITOCHONDRIAL ENZYME; PEROXISOME PROLIFERATOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE;

ANAEROBIC GLYCOLYSIS; ARTICLE; CELL STRAIN HL 60; CONTROLLED STUDY; CORRELATION ANALYSIS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG ACTIVITY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME ASSAY; FATTY ACID OXIDATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; METABOLIC DISORDER; METABOLITE; MITOCHONDRIAL RESPIRATION; NUCLEAR MAGNETIC RESONANCE; RESPIRATORY CHAIN; RHABDOMYOSARCOMA; SARCOMA CELL; SPECTROPHOTOMETRY; SUPERNATANT;

ACETATES; ALANINE; ANIMALS; ANTILIPEMIC AGENTS; BEZAFIBRATE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; ITALY; LACTIC ACID; MAGNETIC RESONANCE SPECTROSCOPY; MICROSCOPY, ELECTRON; MITOCHONDRIA; MITOCHONDRIAL DISEASES; PEROXISOME PROLIFERATORS; RATS; TIME FACTORS; TUMOR CELLS, CULTURED;

ILEX COOKII;

EID: 0345283278     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx0341052     Document Type: Article

References (39)

1. Witzum, J. L. (1996) Drugs used in the treatment of hyperlipoproteinemias. In The Pharmacological Basis of Therapeutics, 9th ed. (Hardman, J. G., Limbird, L. E., Molinoff, P. R., Ruddon, R. W., Goodman, G. A., and Rall, T.W., Eds.) pp 875-897, Pergamon Press, New York.
2. Vamecq, J., and Latruffe, N. (1999) Medical significance of peroxisome proliferator-activated receptors. Lancet 354, 141-147.
3. Issemann, I., and Green, S. (1990) Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347, 645-650.
4. Desvergne, B., and Wahli, W. (1999) Peroxisome proliferator-activated receptors: Nuclear control of metabolism. Endocr. Rev. 20, 649-688.
5. Kersten, S., Desvergne, B., and Wahli, W. (2000) Roles of PPARs in health disease. Nature 405, 421-424.
6. Perutz, M. F., and Poyart, C. (1983) Bezafibrate lowers oxygen affinity of hemoglobin. Lancet 2, 881-882.
7. Scatena, R., Nocca, G., Messana, I., De Sole, P., Baroni, S., Zuppi, C., Castagnola, M., and Giardina, B. (1995) Effects of gemfibrozil on the oxygen transport properties of erythrocytes. Br. J. Clin. Pharmacol. 39, 322-327.
8. Scatena, R., Nocca, G., De Sole, P., Baroni, S., Zuppi, C., Castagnola, M., Giardina, B. (1997) The priming effect of gemfibrozil on reactive oxygen metabolism of phagocytic leukocytes. An intriguing side effect. Clin. Chim. Acta 266, 173-183.
9. Borkird, C., Choi, J. H., and Sung, Z. R. (1986) Effects of 2,4-dichlorophenoxyacetic on the expression of embryogenic program in carrot. Plant Physiol. 81, 1143-1146.
10. Zhou, S., and Wallace, K. B. (1999) The effect of peroxisome proliferators on mitochondrial bioenergetics. Toxicol. Sci. 48, 82-89.
11. Dzhekova-Stojkova, S., Bogdanska, J., and Stojkova, Z. (2001) Peroxisome proliferators: their biological and toxicological effects. Clin. Chem. Lab. Med. 39, 468-474.
12. Youssef, J., and Badr, M. (1998) Extraperoxisomal targets of peroxisome proliferators: mitochondrial, microsomal, and cytosolic effects. Implications for health and disease. Crit. Rev. Toxicol. 28, 1-33.
13. Lazar, M. A. (2001) Progress in cardiovascular biology: PPAR for the course. Nat. Med. 7, 23-24.
14. Sarraf, P., Mueller, E., Jones, D., King, F. J., DeAngelo, D. J., Partridge, J. B., Holden, S. A., Chen, L. B., Singer, S., Fletcher, C., and Spiegelman, B. M. (1998) Differentiation and reversal of malignant changes in colon cancer through PPAR γ. Nat. Med. 4 (9), 1046-1052.
15. Lefebvre, A. M., Chen, I., Desreumaux, P., Najib, J., Fruchart, J. C., Geboes, K., Briggs, M., Heyman, R., and Auwerx, J. (1998) Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCmin/+ mice. Nat. Med. 4 (9), 1053-1057.
16. Scatena, R., Nocca, G., De Sole, P., Rumi, C., Puggioni, P., Remiddi, F., Bottoni, P., Ficarra, S., and Giardina, B. (1999) Bezafibrate as differentiating factor of human myeloid leukemia cells. Cell Death Differ. 6 (8), 781-787.
17. Park, B. H., Breyer, B., and He, T. C. (2001) Peroxisome proliferator activated receptors: roles in tumorigenesis and chemoprevention in human cancer. Curr. Opin. Oncol. 13, 78-83.
18. Maunsbach, A. B. (1994) Cell Biology. A Laboratory Handbook (Celis, J. E., Ed.) Vol. 2, pp 103-125, Academic Press, San Diego, CA.
19. O'Donnel, V. B., Spycher, S., and Azzi, A. (1995) Involvement of oxidants and oxidant-generating enzyme(s) in tumour-necrosis-factor-alpha-mediated apoptosis: role for lipoxygenase pathway but not mitochondrial respiratory chain. Biochem. J. 310, 133-141.
20. Robinson, J. B., Jr., Brent, L. G., Sumegi, B., and Sreve, P. A. (1987) An enzymatic approach to the study of the tricarboxylic acid cycle. In Mitochondria. A Pratical Approach (Barley-Usmar, B. M., Rickwood, D., and Wilson, M. T., Eds.) pp 160-161, IRL, Oxford, U.K.
21. Schrader, M. C., Eskey, C. J., Simplaceanu, V., and Ho, C. (1993) A carbon-13 nuclear magnetic resonance investigation of the metabolic fluxes associated with glucose metabolism in human erythrocytes. Biochim. Biophys. Acta 1182, 162-178.
22. Brambilla, L., Cairo, G., Sestili, P., O'Donnel, V., Azzi, A., and Cantoni, O. (1997) Mitochondrial respiratory chain deficiency leads to overexpression of antioxidant enzymes. FEBS Lett. 418 (3), 247-250.
23. Beutler, E. (1984) Red Cell Metabolism. A Manual of Biochemical Methods, 3rd ed., Grune e Stratton, NY.
24. De Baetselier, P., and Scrham, E. (1986) Luminescent bioassay based on macrophage cell lines. Methods Enzymol. 133, 507-530.
25. Allen, R. C. (1986) Phagocytic leukocyte oxygenation activities and chemiluminescence: a kinetic approach to analysis. Methods Enzymol. 133, 449-492.
26. Crabtree, B., Souter, M. J., and Anderson, S. E. (1989) Evidence that the production of acetate in rat hepatocytes is a predominantly cytoplasmic process. Biochem. J. 257, 673-678.
27. Leighton, F., Bergseth, S., Rortveit, T., Christiansen, E. N., and Bremer, J. (1989) Free acetate production by rat hepatocytes during peroxisomal fatty acid and dicarboxylic acid oxidation. J. Biol. Chem. 264, 10347-10350.
28. Abraham, D. J., Perutz, M. F., and Phillips, S. E. (1983) Physiological and X-ray studies of potential antisickling agents. Proc. Natl. Acad. Sci. U.S.A. 80, 324-328.
29. Perutz, M. F., Fermi, G., Abraham, D. J., Poyart, C., and Bursaux, E. (1986) Hemoglobin as a receptor of drugs and peptides: X-ray studies of the steochemistry of binding. J. Am. Chem. Soc. 108, 1064-1078.
30. Reddy, J. K., and Hashimoto, T. (2001) Peroxisomal β-oxidation and peroxisome proliferator-activated receptor α an adaptive metabolic system. Ann. Rev. Nutr. 21, 193-230.
31. Qu, B., Li, Q., Wong, K. P., Tan, T. M., and Halliwell, B. (2001) Mechanism of clofibrate hepatotoxicity: mitochondrial damage and oxidative stress in hepatocytes. Free Radical Biol. Med. 31, 659-669.
32. Motojima, K. (2002) A metabolic switching hypothesis for the first step in the hypolipidemic effects of fibrates. Biol. Pharm. Bull. 25, 1509-1511.
33. Halliwell, B., and Cutteridge, J. M. C. (1986) Free Radical in Biology and Medicine, Oxford University Press, NY.
34. Lehninger, A. L., Nelson, D. L., and Cox, M. M. (2000) Lehninger Principles of Biochemistry, Worth Publisher, NY.
35. Scheen, A. J. (2001) Thiazolidinediones and liver toxicity. Diabetes Metab. 27, 305-313.
36. Shek, A., and Ferrill, M. J. (2001) Statin-fibrate combination therapy. Ann. Pharmacother. 35, 908-917.
37. Gale, E. A. (2001) Lessons from the glitazones: a story of drug development. Lancet 357, 1870-1875.
38. Hodel, C. (2002) Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol Lett. 128, 159-168.
39. Omar, M. A., and Wilson, J. P. (2002) FDA adverse event reports on statin-associated rhabdomyolysis. Ann. Pharmacother. 36, 288-295.